Russell Buhr is a Respiratory physician affiliated with University of California, Los Angeles. OpenAlex indexes 129 publications with 1,213 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Medical Plaza Suite 365b
Los Angeles, CA 900953075
Telephone
310-825-7921Registry record last updated 26 Aug 2019.
Clinical trials
- Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19
Sponsor: University of California, Los Angeles
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
- Genentech, Inc.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
71.9%Corticosteroid26.6%Trelegy Ellipta32%Fluticasone Propionate21%Dulera20%Breztri Aerosphere17%Symbicort11%Part D<11 patientsbeta2-Adrenergic Agonist23.2%Albuterol Sulfate Hfa90%Striverdi Respimat10%Part D<11 patients+ 3 more classes in this area
Dermatology
13.1%Interleukin-4 Receptor alpha Antagonist13.1%Dupixent Pen100%Part D<11 patientsMetabolism & gastrointestinal
10.1%Corticosteroid10.1%Prednisone100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Understanding uptake of and adherence to clinical practice guidelines for airway disease among patients cared for in the Veterans Health Administration
Va Greater Los Angeles Healthcare System
FY2026I01HX003939 - Understanding uptake of and adherence to clinical practice guidelines for airway disease among patients cared for in the Veterans Health Administration
Va Greater Los Angeles Healthcare System
FY2025I01HX003939
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neutrophil-to-Lymphocyte Ratio as a Biomarker in Clinically Stable Chronic Obstructive Pulmonary Disease: SPIROMICS Cohort
Annals of the American Thoracic Society
2025 - Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin–Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort
Annals of the American Thoracic Society
2025 - Silica Hazards in Engineered Stone Countertop Production: Worker Experiences and Challenges in Los Angeles
American Journal of Industrial Medicine
2025 - Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement
American Journal of Respiratory and Critical Care Medicine
2024 - The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study
American Journal of Respiratory and Critical Care Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”